- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03399253
Chemotherapy Alone Versus Surgery Plus Chemotherapy for Distal Gastric Cancer With One Non-curable Factor
A Prospective,Multicentral,Open-label,Randomized,Controlled,Phase III Clinical Trial of Chemotherapy Alone Versus D2 Gastrectomy and Metastasectomy Plus Chemotherapy for Distal Gastric Cancer With One Non-curable Factor
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Gastric cancer is the fourth most common malignancy worldwide and the second leading cause of cancer-related deaths, with the highest mortality rates reported in East Asia, including China. Many patients are diagnosed at an advanced stage of gastric cancer because of late onset and nonspecific symptoms. The prognosis of patients with advanced gastric cancer with non-curable factors, such as hepatic, peritoneal, or distant lymph node metastases, is poor. Chemotherapy is the standard of care for these patients. Palliative resection or bypass surgery is generally indicated in the presence of major symptoms such as bleeding or obstruction for incurable advanced gastric cancer. The usefulness of gastrectomy and metastasectomy is still unclear.
The REGATTA trial is the first clinical trial to explore the significance of surgery for incurable advanced gastric cancer. However, it concluded an opposite conclusion that gastrectomy followed by chemotherapy did not show any survival benefit compared with chemotherapy alone in advanced gastric cancer with a single non-curable factor. Interestingly, there was a significant interaction between treatment effect and tumor location in subgroup analyses of overall survival. Gastrectomy plus chemotherapy was associated with significantly worse overall survival in patients with upper-third tumors for less chemotherapy cycles. This finding raises the question whether inclusion criteria were restricted to the patients with lower-third tumor, findings of study might have been positive. So we raise this new trail to assess the significance of Gastrectomy and Metastasectomy for Distal Gastric Cancer With One Non-curable Factor.
Studietype
Registrering (Forventet)
Fase
- Fase 2
- Fase 3
Kontakter og plasseringer
Studiekontakt
- Navn: Dazhi Xu, PHD
- Telefonnummer: (+86) 020-87343737
- E-post: xudzh@sysucc.org.cn
Studiesteder
-
-
-
Tianjin, Kina
- Rekruttering
- Tianjin Medical University Cancer Institute and Hospital
-
Ta kontakt med:
- Rupeng Zhang
- Telefonnummer: 13920561244
-
-
Anhui
-
Anqing, Anhui, Kina
- Rekruttering
- Anqing Municipal Hospital
-
Ta kontakt med:
- Yaming Zhang
-
Ta kontakt med:
- Daibin Tang
- Telefonnummer: 13865176528
-
Hefei, Anhui, Kina
- Rekruttering
- The First Affiliated Hospital of Anhui Medical University
-
Ta kontakt med:
- Aman Xu
- Telefonnummer: 13705695470
-
Ta kontakt med:
- Fei Zhong
- Telefonnummer: 18226616729
-
Hefei, Anhui, Kina
- Rekruttering
- Anhui Provincial Hospital
-
Ta kontakt med:
- Xuhui Zhao
- Telefonnummer: 18963789289
-
Ta kontakt med:
- Yifu He
- Telefonnummer: 13485691976
-
Wuhu, Anhui, Kina
- Rekruttering
- First Affiliated Hospital of Wannan Medical College
-
Ta kontakt med:
- Lianghui Shi
- Telefonnummer: 13956159006
-
-
Guangdong
-
Guangzhou, Guangdong, Kina
- Rekruttering
- Yuebei People's Hospital
-
Ta kontakt med:
- Tao Tao Zhang
- Telefonnummer: 13500206389
-
Guangzhou, Guangdong, Kina
- Rekruttering
- Cancer center of Sun Yat-sen University
-
Ta kontakt med:
- Dazhi Xu
- Telefonnummer: 86(020)87343737
- E-post: xudzh@sysucc.org.cn
-
Ta kontakt med:
- Youqing Zhan
- Telefonnummer: 86(020)87343910
- E-post: Zhanyq@sysucc.org.cn
-
-
Jiangxi
-
Nanchang, Jiangxi, Kina
- Rekruttering
- Jiangxi Provincial Cancer Hospital
-
Ta kontakt med:
- Huamin Rao
- Telefonnummer: 13879100685
-
-
Zhejiang
-
Hangzhou, Zhejiang, Kina
- Rekruttering
- Second Affiliated Hospital, School of Medicine, Zhejiang University
-
Ta kontakt med:
- Li Chen
- Telefonnummer: 13958092350
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Lower age limit of research subjects 18 years old and upper age limit of 75 years old.
- PS (ECOG) of 0 or 1.
- Without any other malignancies.
- Written informed consent from the patient.
- Standard gastrectomy with D2 lymphadenectomy for primary cancer
A single non-curable factor was defined by preoperative CT :
hepatic metastasis (H1 or H2; maximum diameter ≤4 cm, number ≤4); peritoneal metastasis (R0 or R1 resection) para-aortic lymph node metastasis (number ≤4) ovarian metastasis adrenal metastasis renal metastasis
- No contraindications to chemotherapy, including normal peripheral blood routine, liver and kidney function and electrocardiogram (WBC≥4.0 x 109 /L, NEU≥1.5 x 109 /L,PLT≥100 x 109 /L and HGB≥90g/L)
Exclusion Criteria:
- Female in pregnancy or lactation.
- Supraclavicular lymph nodes metastases,lung and bone metastases.
- Massive ascites or cachexia.
- Extensive cancer metastases of liver, peritoneal metastasis,para-aortic lymph node
- Patients participating in any other clinical trails currently,or participated in other trails within 1 months.
- Suffering from other serious diseases, including cardiovascular, respiratory, kidney, or liver disease, complicated by poorly controlled hypertension, diabetes, mental disorders or diseases.
- Poor treatment compliance of patients
- The group of chemotherapy alone accepts gastrectomy for bleeding or obstruction
- Failure of R0 or R1 metastasectomy and gastrectomy with D2 lymphadenectomy
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Aktiv komparator: Chemotherapy
chemotherapy with capecitabine and oxaliplatin (eight 3-week cycles of oral capecitabine 1000 mg/m² twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or progress of disease
|
capecitabine and oxaliplatin (eight 3-week cycles of oral capecitabine 1000 mg/m² twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or progress of disease
Andre navn:
|
Eksperimentell: Surgery+Chemotherapy
D2 Gastrectomy and Metastasectomy + chemotherapy with capecitabine and oxaliplatin (eight 3-week cycles of oral capecitabine 1000 mg/m² twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or progress of disease
|
capecitabine and oxaliplatin (eight 3-week cycles of oral capecitabine 1000 mg/m² twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or progress of disease
Andre navn:
D2 gastrectomy + metastasectomy
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Overall survival
Tidsramme: 5-year
|
OS
|
5-year
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
progression free survival
Tidsramme: 3-year
|
PFS
|
3-year
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Dazhi Xu, PHD, Sun Yat-sen University
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- GCGC004
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Magekreft
-
Washington University School of MedicineNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)FullførtRoux-en-Y Gastric Bypass | Bariatrisk kirurgi | Vertical Sleeve Gastrectomy | Magebånd | Bypass, GastricForente stater
-
Medtronic - MITGFullført
-
Wageningen UniversityRijnstate HospitalUkjentRoux-en-Y Gastric BypassNederland
-
North Dakota State UniversityNeuropsychiatric Research Institute, Fargo, North DakotaFullførtRoux en Y Gastric BypassForente stater
-
DuomedAktiv, ikke rekrutterendeOvervekt | Gastrectomi | Roux-en-Y Gastric Bypass | Mini Gastric BypassBelgia
-
Olympus Corporation of the AmericasUnity Health TorontoFullført
-
North Dakota State UniversityNational Institutes of Health (NIH)FullførtRoux en Y Gastric Bypass kirurgiForente stater
-
North Dakota State UniversityNeuropsychiatric Research Institute, Fargo, North DakotaFullførtSleeve Gastrectomy | Roux en Y Gastric BypassForente stater
-
Rijnstate HospitalFullførtRoux-en-Y Gastric Bypass | Magetømming | Bariatrisk kirurgiNederland
-
Rijnstate HospitalFullførtBariatrisk kirurgi | Jern absorpsjon | Roux- en -y Gastric BypassNederland
Kliniske studier på chemotherapy
-
Eli Lilly and CompanyFullførtHER-2 positiv brystkreft | Hormonreseptor positiv brystkreftSpania, Forente stater, Korea, Republikken, Belgia, Frankrike, Tyskland, Italia, Australia, Argentina, Canada, Storbritannia, Mexico, Brasil, Hellas
-
H. Lee Moffitt Cancer Center and Research InstituteServierRekrutteringAkutt lymfatisk leukemiForente stater
-
Memorial Sloan Kettering Cancer CenterAktiv, ikke rekrutterende
-
Fondazione del Piemonte per l'OncologiaFullført